The acute respiratory distress syndrome (ARDS) is a disorder of diffuse lung injury secondary to a wide variety of clinical insults (eg, sepsis) and is manifested by impaired oxygenation, pulmonary edema, and decreased static and dynamic compliance. More We designed this prospective, randomized, double-blind, placebo-controlled, crossover study to confirm the presence of increased airflow resistance in patients with ARDS and to determine whether these changes are reversible using an aerosol ,3-agonist (metaproterenol). Finally, we wanted to determine if such therapy has an effect on gas exchange and physiologic dead space.
The acute respiratory distress syndrome (ARDS) is a disorder of diffuse lung injury secondary to a wide variety of clinical insults (eg, sepsis) and is manifested by impaired oxygenation, pulmonary edema, and decreased static and dynamic compliance. More recently, airflow resistance has been shown to be increased in humans with ARDS. We designed a prospective, randomized, placebo-controlled, crossover trial to determine the presence and reversibility of increased airflow resistance in ARDS. We studied eight mechanically ventilated patients with ARDS (criteria: PaO2 .70 mm Hg with FIo2 .0.4; diffuse bilateral infiltrates; and pulmonary artery wedge pressure .18 mm Hg). Each was intubated with a No. 8.0 orotracheal tube. We measured dynamic compliance (Cdyn), static compliance (Cstat), airflow resistance across the lungs (RL), shunt fraction (Qs/Qt on F1o2=1.0), minute ventilation (VE), PaO2/ PAO2, and dead space to tidal volume ratio (VD/VT). Patients were blindly assigned to receive either metaproterenol (1 mL 0.5% in 3 mL saline solution) or saline solution (4 mL) aerosolized over 1S min 6 h apart and in random order so that patients served as their own conThe acute respiratory distress syndrome (ARDS) is observed in patients with diverse etiologies and is marked by abnormalities of lung mechanics and gas exchange thought secondary to diffuse lung inflammation as shown in humans'14 and in animal models. [5] [6] [7] [8] [9] [10] [11] Reduced lung compliance is a hallmark of the syndrome and has generally been considered the primary lung mechanics abnormality. Previous investigations of gas exchange and lung mechanics abnormalities in ARDS have focused on parenchymal abnormalities resulting from atelectasis, alveolar and interstitial edema, and airway secretions. The contribution of increased resistance to gas exchange and other lung mechanics abnormalities has been examined in detail only recently.'2"13 In the sheep endotoxin model of diffuse lung injury, alterations in resistance, both early and late, following endotoxin are due to prolonged bronchoconstriction14 and are reversible with nitroprusside,14 cyclooxygenase inhibition,15 and d-agonists (metaproterenol). 16 Airway hyperreactivity seems to contribute to the increased airflow resistance in patients with ARDS12"3 both acutely and well into the prolonged recovery phase.17 '19 We designed this prospective, randomized, double-blind, placebo-controlled, crossover study to confirm the presence of increased airflow resistance in patients with ARDS and to determine whether these changes are reversible using an aerosol ,3-agonist (metaproterenol). Finally, we wanted to determine if such therapy has an effect on gas exchange and physiologic dead space.
METHODS

Patient Selection
We studied eight patients who had ARDS and who were in the intensive care units of Vanderbilt University Medical Center. Patients who had an illness known to be associated with ARDS and who met all the following criteria were eligible for study: (1) arterial blood gases revealing a partial pressure of arterial oxygen of (PaO2) <70 mm Hg while they were breathing at least 40% oxygen or a ratio of partial pressure of arterial oxygen to partial pressure of alveolar oxygen (PaO2/PAO2) of .0.3 (regardless of the level of positive end-expiratory pressure [PEEP]); (2) bilateral diffuse infiltrates on chest radiography compatible with pulmonary edema; (3) a pulmonary artery wedge pressure < 18 mm Hg; and (4) inspiratory inflation pressure (peak dynamic pressure minus PEEP) from the ventilator manometer >30 cm H20 (tidal volume 10 mL/kg, inspiratory flow 60 L/min). Patients were excluded if they had received /-agonists of any kind or amount in the 8 h immediately preceding the study. Exclusions were made for pregnancy, age younger than 7 years, the presence of severe shock (defined as a mean arterial blood pressure of less than 60 mm Hg), or a history of obstructive airways disease (asthma or COPD). Informed consent was obtained from the patient when appropriate or the next of kin. This study was approved by the committee for the protection of human subjects at Vanderbilt University.
Randomization
Patients were studied in a prospective, randomized, placebocontrolled fashion and were crossed over to receive the alternate intervention by a computer-generated randomization schedule. Syringes numbered sequentially were filled with either 1 mL of 0.5% metaproterenol solution mixed with 3 mL of normal saline solution or 4 mL solution of normal saline solution (placebo). Depending on the order of entry into the study, patients received an aerosol of either placebo or metaproterenol (in a doubleblinded fashion) given with the output of the aerosol device connected directly to the endotracheal tube. Six hours after the first aerosol dose was given, the opposite preparation was administered to the same patient.
Clinical and Routine Laboratory Data
Upon the patient's entry into the study, a clinical history was obtained and a physical examination was performed. The suspected cause, the time of the pulmonary insult (ie, the underlying process thought to be responsible for the development of ARDS), and the time of onset of ARDS were recorded.
Cardiac output (thermodilution), central venous pressure, pulmonary artery pressure, and pulmonary artery wedge pressure were measured with the patient supine and at end-expiration. Heart rate and systemic blood pressure was monitored in all of the patients. Mechanical ventilation was maintained throughout these measurements and all measurements in a given patient were made under the same conditions. The zero reference point for the hemodynamic measurements was the midaxillary line.
Gas exchange was assessed by measurement of arterial blood gases, PEEP requirements, minute ventilation, and respiratory rate. Standard calculations were used to measure intrapulmonary shunting, with the patient breathing 100% oxygen for 15 min and arterial and mixed venous oxygen tension and saturation being measured simultaneously. In six patients, dead space to tidal volume ratio (VD/VT) was measured by collecting expired gases over 5 min in a vinyl breathing bag (Douglas, Warren Collins, Braintree, Mass) and expired Pco2 was measured with a carbon dioxide analyzer (Beckman Medical Gas Analyzer LB-2, Fullerton, Calif). The dead space of the ventilator tubing (using the correction factor of 3 mL of dead space/cm H20 peak airway pressure/respiratory cycle) was subtracted from the measured tidal volume.20 The minute ventilation and dead space were determined simultaneously.
Lung Mechanics Measurements
Dynamic compliance (Cdyn) and airflow resistance (RL) were measured at the bedside in all eight mechanically ventilated patients with ARDS using methods previously reported. 21 Briefly, Cdyn and RL were derived mathematically from four primary measurements: airflow, tidal volume, airway pressure (Paw), and midesophageal pressure. (Fig 1) . Flow signals were calibrated at the bedside with a rotameter driven by pressurized air. Volume was measured by integrating the flow signal and calibrated using a 3-L syringe. Tubing that linked the pressure ports with their transducers was oscilloscopically adjusted for length to assure that the primary and integrated flow signals were in phase with the pressures relevant to the measurements of interest. Airway pressure was measured using a small-caliber polyethylene catheter (internal diameter, 1.67 mm; outside diameter, 2.42 mm) with multiple side holes and an occluded end hole placed (0. The eight patients with ARDS selected for study had all been orally intubated with No. 8.0 (8.0 mm inside diameter) endotracheal tubes and required mechanical ventilation. We checked for leaks in the system by auscultating the neck for leaks around the endotracheal tube cuff and comparing inspiratory volume to expiratory volume with the pneumotach. Lung mechanics measurements were made at peak flow rates of 50 (actual delivered flow ranged within ±5 L/min depending on the type of ventilator). Tidal volume was determined by the primary care physician and averaged 638 ± 81 mL. The airway catheter with multiple side holes was positioned in the tracheal lumen 0.5 cm past the distal end of the endotracheal tube to eliminate the contribution of the endotracheal tube to the lung mechanics measurement.23 '25 Five minutes prior to each lung mechanics measurement, each patient was given a sigh breath equal to twice the set tidal volume and was suctioned to minimize the contribution of airway secretions to airflow resistance. The PEEP settings were held constant through all measurements in a given patient. A single representative breath was frozen on the calibrated oscilloscope and photographed for data analysis. The first aerosol was then administered and the hemodynamics, lung mechanics, and blood gas measurements were repeated 30, 60 , and 120 min later. Six hours after the first aerosol was given, the opposite aerosol preparation was administered following establishment of new baseline measurements. The subsequent measurements were repeated as before.
Definitions: Patients who met entry criteria were defined as having ARDS. The definitions of the principal causes of ARDS were modifications of those described by Pepe et al. 26 Eight patients with ARDS from the intensive care units at Vanderbilt University Hospital were studied, including two men and six women with a mean age of 51 ± 7 years. Although two of the eight patients were smokers prior to hospitalization, neither had physical evidence, laboratory findings, or a history of previously existing lung disease. As Table 1 shows, physiologic variables were similar at the beginning of the metaproterenol and placebo portions of the trial, precluding a carryover effect and also indicative of the crossover design of the study. The mean shunt, VD/VT, PEEP level, and hemodynamic variables were similar to those we have reported previously.27 When measured by the ventilator manometer, the mean peak pressure at entry was 59 ± 4 cm H20 at peak flow rates of 50 to 80 L/min, while the mean peak minus plateau pressure was 13±2 cm H20.
The mean time interval between meeting our criteria for ARDS and entry into the study was 5.1 ± 1.5 hours, while the period between clinical onset of ARDS and entry was 80.5 ± 27.7 h. The difference in these time intervals was mostly accounted for by delays in documentation of pulmonary artery wedge pressure. ARDS was attributed to sepsis in three patients, aspiration in two, shock in two, and multiple causes in one patient (sepsis plus pancreatitis).
Baseline measurements were similar between treatment groups with regard to all pulmonary physiologic measurements (Table 1) . There was no carryover of metoproterenol's effects in those patients who received the metaproterenol arm first in the study (Table 1, Figs 2 and 3) .
Aerosolized placebo had no effect on any of the variables measured. Aerosolized metaproterenol increased heart rate (120±6 to 130±10 beats/min) and mean arterial pressure (80 ± 3 to 90 ± 5 mm Hg) at 30 min compared with baseline (p<0.05) but had no effect on cardiac index, mean pulmonary artery pressure, or mean pulmonary artery wedge pressure.
Aerosolized This trend was paralleled by a nonstatistically significant increase in arterial partial oxygen pressure on FIo2=1.0 by 120 min (205±30 mm Hg to 241 ±28) (p=0.11). While metaproterenol tended to improve oxygenation, there was no effect on pulmonary shunting (0.36 ± 0.04 to 0.36 ± 0.04), minute ventilation (VE) 16 ± 3 L/min to 17 ± 2), or (VP /VT) (0.74 ± 0.03 to 0.76 ± 0.02) at 30, 60, and 120 min following treatment (p>0.05).
DISCUSSION
Reduced lung or thoracic compliance, more specifically static compliance, is usually considered the primary disorder of lung mechanics in ARDS. The contribution of airflow resistance to lung mechanics and gas exchange abnormalities in ARDS had not been extensively studied until recently.'2"1330 In a previous study, we were able to show that resistance to airflow across the lung was significantly greater in 12 patients with ARDS than normal controls, 6.15 ± 0.08 vs 0.88 ± 0.08 H20/L/s, respectively.13 Although the mechanisms of the increased RL are unknown, possible explanations include decreased lung volumes and/or increased airway reactivity. Processes that produce airway inflammation often lead to heightened airway resistance and reactivity; therefore, ARDS resulting from specific stimuli such as noxious gas inhalation, endotoxemia, or gastric aspiration might be complicated by airway hyperreactivity.30-32 Airway hyperreactivity has been shown to occur in animal models of septic lung injury. In the sheep endotoxin model of acute lung injury, acute endotoxemia provokes an abrupt increase in airflow resistance and a reduction in dynamic compliance 1533 and these changes appear to be at least partially granulocyte dependent.34'35 Endotoxin also augments the responsiveness of the sheep airway to histamine.31
It has previously been shown in sheep that the sustained alterations in lung mechanics following endotoxin are reversible with nitroprusside and metaproterenol and that reversal does not affect the alveolar to arterial oxygen partial pressure gradient on room air.1416 These animal experiments suggest that airway resistance can be increased by endotoxemia and may have a reversible component. Increased airflow resistance (both pulmonary tissue and airway) has been shown to be increased in patients with ARDS.36 Though airflow resistance has not been specifically measured in patients with sepsis without ARDS, previous studies in sepsis suggest that increased airway pressures are reverible by ibuprof en.37 Clinically heightened airway responsiveness has also been reported to occur in long-term survivors of ARDS when measured after recovery, suggesting the possibility that acute airway injury may also cause a permanent change in airway reactivity.171'9 Therefore, we hypothesized that airflow resistance contributes significantly to abnormalities in ARDS and could be reversed with aerosolized bronchodilator therapy.
Our randomized and crossover design was successful in that the variables we measured in our patients were nearly identical at the beginning of each phase of the study. The comparability of the baseline data also indicates that there was no carryover effect in the placebo arm in those patients receiving metaproterenol first. The largest group of patients had sepsis as their underlying etiology (38%) with aspiration (25%) and shock (25%) as the second most frequent causes. All of the patients had markedly increased RL and decreased Cdyn at entry and patients receiving metaproterenol experienced an immediate reduction in RL and an increase in Cdyn. Peak and plateau pressures measured in the trachea were also reduced. It is also important to note that all of the airway mechanics data reported herein were obtained using airway pressure measured in the trachea. Thus, the endotracheal tube's significant contribution to the lung mechanics measurements as shown by ourselves and others was excluded. 21'2238'39 Only two of eight patients were smokers at the time of onset of illness. None of our patients had a history of obstructive airway disease. The sputum Wright stain for eosinophils was negative in each patient.
The effects of aerosolized metaproterenol on lung mechanics in this study were similar to effects we have previously observed in the sheep endotoxin model16 and by others who reported their findings in humans receiving intravenous salbutamol.36 In the sheep, sustained alterations in airflow resistance were decreased by half and Cdyn increased by 50 to 60% following metaproterenol aerosol. Data with cyclooxygenase inhibitors and thromboxane receptor antagonists suggest that part of these alterations in lung mechanics may be mediated by constrictor prostanoids. 16 Further studies with such agents in ARDS are indicated to elucidate the mechanism of the alterations in lung mechanics.
Metaproterenol tended to improve oxygenation as measured by PaO2/PAO2 (p=0. 11), but no effect was seen on directly measured pulmonary shunting. The disparity in the two measures of oxygenation could be attributed to improvement in ventilation/perfusion matching or to a reduction in the work of breathing and subsequent oxygen debt of the respiratory muscles as lung mechanics were improved though these were not measured directly. Despite the observed bronchodilation, there also was no worsening of dead space in our patients, suggesting that airways connected to poorly perfused areas of lung were not recruited by bronchodilation or that bronchodilation occurred mainly in the central airways.
Another effect of bronchodilation in our patients was a reduction in peak and plateau pressures. The former was not unexpected considering the previously presented animal data. However, the reduction in plateau airway pressure was rather interesting. This finding suggests the possibly that gas exchanging lung units were recruited or that tissue forces were somehow altered. We cannot distinguish between the two with the data we collected since we did not directly measure lung volume. Micro and macro barotrauma related to high mean airway pressures in patients with ARDS contributes significantly to morbidity and mortality. Reduction in airway pressures with bronchodilation could result in a reduction in the risk of lung parenchymal trauma in mechanically ventilated patients. 40 We conclude that increased resistance to airflow across the lungs is markedly increased in patients with ARDS and contributes to work of breathing. The rapid reversibility with aerosolized metaproterenol suggests that the changes are due at least in part to bronchospasm. The improvement in oxygenation (though minimal) may be due to improvement in ventilation/perfusion matching and/or to a decrease in oxygen consumption by the respiratory muscles.
However, further studies are needed to determine the long-term effects of repeated doses of bronchodilators on morbidity and mortality and the mechanisms of increased airflow resistance in ARDS before a firm recommendation can be made for their routine use in mechanically ventilated patients with ARDS. In those patients with documented bronchospasm (wheezing) or with markedly increased airflow resistance (directly measured or estimated from very high peak and plaueau pressures), a trial of aerosolized bronchodilator therapy may be indicated.
